<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03412864</url>
  </required_header>
  <id_info>
    <org_study_id>KS-INVOSSA-PMS</org_study_id>
    <nct_id>NCT03412864</nct_id>
  </id_info>
  <brief_title>A Post Marketing Surveillance Study of INVOSSA K Inj.</brief_title>
  <official_title>Post Marketing Surveillance on Safety and Effectiveness Evaluation of INVOSSA K Inj.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kolon Life Science</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kolon Life Science</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is post-marketing surveillance of Invossa K injection in patients with
      osteoarthritis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Anticipated">July 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 11, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>AEs (Adverse Events)</measure>
    <time_frame>0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)</time_frame>
    <description>Changes of incidence rate in AEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>100 mm VAS (Visual Analog Scale)</measure>
    <time_frame>0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)</time_frame>
    <description>Changes of 100 mm VAS at each visit (Scale : 0~100, 0 : No pain, 100 : Worst imaginable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination (Knee joint swelling)</measure>
    <time_frame>0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)</time_frame>
    <description>Changes of Knee joint swelling at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination (Tenderness)</measure>
    <time_frame>0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)</time_frame>
    <description>Changes of tenderness at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination (ROM)</measure>
    <time_frame>0 month(visit 1), 1 month(visit 2) and 6 Months(visit 3)</time_frame>
    <description>Changes of ROM(Range Of Motion) at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General efficacy evaluation</measure>
    <time_frame>6 Months(visit 3)</time_frame>
    <description>General efficacy evaluation was assessed by following 4 criteria. (Improved, Not changed, Worsened, Unassessable)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Osteoarthritis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male or female patients over 19 years with osteoarthritis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients over 19 years

          2. Patients who diagnosed with osteoarthritis will plan to INVOSSA K Inj. injection and
             suitable for following criteria :

             - Moderate knee osteoarthritis (Kellgren &amp; Lawrence grade 3) with persistent symptoms
             (pain, etc.) in spite of conservative therapy (medication, physical therapy, etc.) for
             more than 3 months

          3. Patients (or substitute) who is provided all information regarding participation of
             this PMS signed the informed consent form

        Exclusion Criteria:

          1. Pregnant or breastfeeding female

          2. Patients who have administered corticosteroid before INVOSSA K Inj. injection within
             the past 30 days

          3. Patients who have severe disease such as heart, liver, kidney disease or other severe
             complications

          4. Patients who rheumatoid arthritis, gouty arthritis, autoimmune disease associated
             arthritis except for osteoarthritis

          5. Patients with a medical history of allergic diseases or patients with a medical
             history of anaphylactic reactions (including patients with a history of
             hypersensitivity reactions to the components of this drug, including dimethylsulfoxide
             (DMSO), mannitol, dextran 40 or bovine proteins)

          6. Patients who have been treated with injections to the target knee within the past
             three months or patients with a past history of surgery, including arthroscope, within
             the past six months

          7. Patients currently with leukemia or malignant tumors such as osteochondroma,
             chondroblastoma, cartilaginous mucinous fibrous tumor, chondroma and chondrosarcoma,
             which may be exacerbated by administration of INVOSSA-K inj. or patients with a
             history thereof

          8. Patients with Kellgran &amp; Lawrence grade 4 osteoarthritis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oog Jin Shon, MD, PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeungnam University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Young-ji Bae, MS</last_name>
    <phone>82-02-3677-4198</phone>
    <phone_ext>4198</phone_ext>
    <email>youngji_bae5@kolon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jong Hyuk Jung, MS</last_name>
    <phone>82-02-3677-4236</phone>
    <phone_ext>4236</phone_ext>
    <email>jonghyuk_jung@kolon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oog Jin Shon, MD, PhD.</last_name>
      <phone>82536203115</phone>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2018</study_first_submitted>
  <study_first_submitted_qc>January 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chondrocyte cells</keyword>
  <keyword>osteoarthritis</keyword>
  <keyword>gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

